Core Viewpoint - The A-share ophthalmology medical concept stocks experienced a collective surge, with several companies reaching their daily limit up, indicating strong market interest and potential growth in the sector [1][2]. Group 1: Stock Performance - Companies such as Shapais, Innovation Medical, and Xingqi Eye Medicine saw significant stock price increases, with Xingqi Eye Medicine rising over 14% and Shapais reaching a limit up [1][2]. - The ophthalmology sector index rose by 2.17%, reflecting overall positive sentiment in the market [2]. Group 2: Market News - Recent rumors indicated that the Henan Provincial Eye Hospital would stop supplying its self-made 0.01% atropine sulfate eye drops due to the expiration of its registration, which has led to increased attention on the market for similar products [3][4]. - The hospital confirmed that the 0.01% atropine sulfate eye drops had ceased production since December of the previous year, with current sales being from existing inventory [3]. Group 3: Product and Market Dynamics - Atropine sulfate eye drops have gained recognition as a "myopia miracle drug," particularly for children aged 6 to 12, and are recommended in various authoritative guidelines for myopia management [4]. - Xingqi Eye Medicine's atropine sulfate eye drops received approval for market entry in March 2024, leading to a significant increase in its stock price and revenue growth [4]. - In 2024, Xingqi Eye Medicine reported a revenue of 1.943 billion yuan, a year-on-year increase of 32.42%, and a net profit of 338 million yuan, up 40.84% [4]. Group 4: Competitive Landscape - The market for atropine sulfate eye drops is becoming increasingly competitive, with several companies, including Zhaoke Ophthalmology and Hengrui Medicine, advancing their own products [5]. - Shapais is also in the process of developing its own version of atropine sulfate eye drops, which is currently in Phase III clinical trials [5]. - Xingqi Eye Medicine is expected to continue its upward trajectory with ongoing product iterations and new submissions for market approval [5].

Core Viewpoint - The article highlights a significant surge in the A-share ophthalmology medical concept stocks, driven by market rumors regarding the supply issues of a specific eye drop formulation, which has led to increased investor interest and stock price increases for several companies in the sector [1][2]. Company Performance - On September 1, A-share ophthalmology stocks saw collective gains, with notable performances including: - Xingqi Eye Medicine up 14.65% to 77.54 - Innovation Medical up 10% to 25.19 - Shapuaisi up 9.95% to 8.40 - Baicheng Pharmaceutical up 8.46% to 62.45 [1][2]. Market Dynamics - Recent rumors indicated that the Henan Provincial Eye Hospital would stop supplying its self-made 0.01% atropine sulfate eye drops due to expired registration, which has been confirmed by hospital staff. This product will cease supply after September 6, 2023, while other concentrations remain in production [3][4]. - Atropine sulfate eye drops have gained recognition as a "myopia miracle drug," particularly for children aged 6 to 12, and are recommended in various authoritative guidelines for myopia management [4]. Competitive Landscape - The market for atropine sulfate eye drops is becoming increasingly competitive, with several companies, including Zhaoke Ophthalmology and Hengrui Medicine, advancing their own formulations. Shapuaisi is also in the process of clinical trials for its version [5][6]. - Xingqi Eye Medicine has seen substantial growth, with revenues of 1.943 billion in 2024, a 32.42% increase year-on-year, and a net profit of 338 million, up 40.84% [4]. In the first half of 2025, the company reported revenues of 1.163 billion, a 30.38% increase, and a net profit of 335 million, a remarkable 97.75% increase [4].

Report Summary 1. Report Industry Investment Rating No investment rating information is provided in the report. 2. Core Viewpoints - The company adheres to independent R & D, strengthens its core competitiveness, expands the market, and optimizes the customer structure. In the first half of 2025, both revenue and net profit maintained stable growth [30]. - The company's products, such as Xingqi Meiopin and Zirun, have broad market prospects. Xingqi Meiopin has a good market performance, and Zirun is expected to continue to contribute to the company's growth [30][43]. - The company will continue to increase investment in the field of ophthalmic innovative drugs, improve its independent innovation ability, and layout and develop more competitive ophthalmic innovative drug products [32]. 3. Summary by Directory 3.1. Research Basic Situation - Research object: Xingqi Eye - drops [16] - Industry: Chemical pharmaceuticals [16] - Reception time: September 1, 2025 [16] - Reception personnel: Vice - chairman and board secretary Zhang Shaoyao, director and general manager Gao E, director, deputy general manager and CFO Cheng Ya'nan, director and deputy general manager Yang Qiang [16] 3.2. Detailed Research Institutions - Many institutions participated in the research, including securities companies such as Guosheng Securities, Guotou Securities, and GF Securities; fund management companies such as Huaxia Fund, Hui'an Fund; and other types of institutions like Guojin Medicine, China International Capital Corporation [17][18]. 3.3. Main Content 3.3.1. 2025 Semi - annual Performance - Revenue in the first half of 2025 was 1.163 billion yuan, a year - on - year increase of 30.38%. Net profit attributable to shareholders of the listed company was 335 million yuan, a year - on - year increase of 97.75% [30]. - The proposed profit distribution plan for the first half of 2025 is to distribute 7 yuan in cash for every 10 shares based on the total share capital of 245 million shares, subject to the approval of the company's second interim shareholders' meeting in 2025 [30]. 3.3.2. Investor Questions and Answers - **Atropine Promotion and Sales** - Xingqi Meiopin has achieved wide coverage in in - hospital and out - of - hospital channels and received good market feedback. There are over 500 professional promotion personnel in the myopia prevention and control field, and the number will be adjusted according to relevant factors [30]. - It has been widely introduced into public hospitals and major private ophthalmic groups, and only one province has not completed drug access. As of the end of June, it has been stocked in nearly 17,000 retail pharmacies and launched on multiple platforms [31][32]. - The sales growth is driven by full - channel marketing, multi - party cooperation, and professional academic promotion. The company's core goals this year are to let over 20 million people know the myopia treatment plan and promote over one million children to receive standardized drug intervention [34][35]. - **R & D Pipeline** - The Class 1 therapeutic biological product SQ - 22031 eye drops have completed Phase I clinical trials and are conducting Phase II clinical trials for neurotrophic keratitis. The SQ - 129 vitreous slow - release injection has completed pre - clinical research and will conduct clinical trials for macular edema after approval [32]. - The company obtained the clinical summary report of "Efficacy and safety of different concentrations of atropine sulfate eye drops (0.02% and 0.04%) in delaying myopia progression in children" in October 2024, and the product is under review by the drug evaluation center [33][35]. - **Other Products and Market Outlook** - Zirun has achieved double - digit growth in the first half of 2025, and its annual sales outlook is optimistic due to the large number of dry - eye patients and its inclusion in the national medical insurance negotiation catalog [43]. - The company will continue to expand its international market for low - concentration atropine eye drops and is in the preliminary communication stage with overseas partners [46]. - The company plans to build a comprehensive R & D headquarters in the Shenyang area of the China (Liaoning) Pilot Free Trade Zone, focusing on ophthalmic R & D and equipped with top - notch R & D teams [47].

Core Viewpoint - The recent surge in A-share ophthalmology stocks is driven by the news of the discontinuation of a specific eye drop formulation, which has led to increased investor interest in alternative products and companies in the sector [1][2]. Company Developments - Shapuaisi (603168.SH) and Innovation Medical (002173.SZ) reached their daily limit up, while Xingqi Eye Medicine (300573.SZ) rose over 14%, and Baicheng Pharmaceutical (301096.SZ) increased by over 8% [1]. - Xingqi Eye Medicine's atropine eye drops have seen significant stock price increases following their approval for market release, with the stock reaching a historical high of 152.04 yuan per share on May 30, 2024 [2]. - In 2024, Xingqi Eye Medicine reported a revenue of 1.943 billion yuan, a year-on-year increase of 32.42%, and a net profit of 338 million yuan, up 40.84% [2]. Market Dynamics - The market for atropine eye drops is becoming increasingly competitive, with several companies, including Zhaoke Ophthalmology and Heng Rui Medicine, actively pursuing approvals for their own formulations [3]. - The discontinuation of the 0.01% atropine eye drops from Henan Provincial Eye Hospital is expected to create opportunities for other companies to capture market share [1][3]. - The ongoing development of new formulations, such as Xingqi Eye Medicine's upcoming SQ-729 eye drops, is anticipated to enhance the company's product offerings and performance [3].

9月1日，A股市场整体上涨。 截至收盘，上证指数收报3875.53点，上涨0.46%，深证成指收报12828.95点，上涨1.05%，创业板指收 报2956.37点，上涨2.29%，北证50指数下跌0.36%。A股市场合计成交27780.05亿元，较上一交易日减少 525.88亿元。 1. A股市场全天资金净流出364.22亿元 今日A股市场主力资金开盘净流出183.69亿元，尾盘净流出41.39亿元，A股市场全天资金净流出364.22 亿元。 4.利欧股份主力资金净流入18.51亿元居首 | | | 沪深两市近五日主力资金流向情况(亿元) | | | | --- | --- | --- | --- | --- | | 日期 | | 净流入金额 开盘净流入 | | 尾盘净流入 超大单净买入 | | 2025-9-1 | -364.22 | -183.69 | -41.39 | -131.29 | | 2025-8-29 | -527.66 | -222. 09 | -41.04 | -247.22 | | 2025-8-28 | -389.74 | -174. 52 | 88. 42 | -122. 21 | ...

9月1日，A股市场整体上涨。 截至收盘，上证指数收报3875.53点，上涨0.46%，深证成指收报12828.95点，上涨1.05%，创业板指收 报2956.37点，上涨2.29%，北证50指数下跌0.36%。A股市场合计成交27780.05亿元，较上一交易日减 少525.88亿元。 1. A股市场全天资金净流出364.22亿元 今日A股市场主力资金开盘净流出183.69亿元，尾盘净流出41.39亿元，A股市场全天资金净流出364.22亿 元。 | | | 沪深两市近五日主力资金流向情况(亿元) | | | | --- | --- | --- | --- | --- | | 日期 | | 净流入金额 开盘净流入 | | 尾盘净流入 超大单净买入 | | 2025-9-1 | -364. 22 | -183.69 | -41.39 | -131.29 | | 2025-8-29 | -527.66 | -222. 09 | -41.04 | -247.22 | | 2025-8-28 | -389.74 | -174. 52 | 88. 42 | -122. 21 | | 2025-8-27 | -913. 3 ...

Core Insights - The company, Zhaoke Ophthalmology (6622.HK), has three core drug candidates that have entered the New Drug Application (NDA) stage, with expected approvals in China in the second and third quarters of next year [1] - The two formulations of atropine eye drops at concentrations of 0.01% and 0.02% are aimed at controlling the progression of myopia in adolescents [1] - Zhaoke's 0.01% atropine eye drops, branded as "Mei Le Tong," is the second product in the industry to receive an application acceptance, following the approval of a similar product by competitor Xingqi Eye Pharmaceutical last March [1] Product Comparison - Zhaoke's COO, Dai Xiangrong, noted that their product has a pH value close to 6, making it more neutral and less irritating compared to the competitor's product [1] - The industry estimates that Xingqi's 0.01% atropine eye drops generated sales of over 700 million RMB within nine months of its launch [1] - Although Zhaoke did not provide a specific sales target for its 0.01% atropine eye drops, it indicated that it would use the competitor's sales as a benchmark [1]

| 代码 | 名称 | | 最新 | 涨幅 | | --- | --- | --- | --- | --- | | 000001 | 上证指数 | | 3875.53 | +0.46% | | 399001 | 深证成指 | | 12828.95 | +1.05% | | 399006 | 创业板指 | . | 2956.37 | +2.29% | | 000016 | FIF50 | . | 2981.20 | +0.16% | | 000300 | 沪深300 | . | 4523.71 | +0.60% | | 000688 | 科创50 | 9 | 1357.15 | +1.18% | | HSI | 恒生指数 | | 25617.42 | +2.15% | | HSTECH | 恒生科技指数 | | 5798.96 | +2.20% | 盘面上，黄金、通信设备、创新药、食品加工等板块涨幅居前，航天装备、保险、风电设备、小家电等板块跌幅居前。 今日，A股整体震荡上扬，创业板指高开高走涨逾2%，站稳2900点，再创3年半来新高，深证成指、沪深300、中证500等也纷纷创出多年来新高，市场成 交小幅萎缩至 ...

Group 1 - The A-share market experienced a collective rise on September 1, 2025, with a trading volume of approximately 27,499.61 billion yuan, driven by sectors such as gold, CPO, innovative drugs, and storage chips [1] - As of August 29, 2025, the A-share financing balance reached a new high of 22,454.72 billion yuan, just 211.63 billion yuan short of the historical peak, with the Shenzhen market financing balance also hitting a record [1] - Market sentiment has been buoyed by factors such as the expectation of a Federal Reserve interest rate cut, significant upcoming events, structural prosperity in mid-year reports, and advancements in the domestic AI industry, leading to substantial inflows of incremental capital [1] Group 2 - The A500 index rose by 0.85% as of September 1, 2025, with the leading A500 ETF (563800) increasing by 0.62%, marking three consecutive days of gains [2] - Financial institutions suggest that the A-share market's chip structure has improved following significant fluctuations, with the "anti-involution" policy and demand-side policies being crucial for market performance [2] - Core assets are becoming a focal point for the market, with expectations of a recovery in ROE as net profit margins improve and turnover stabilizes, indicating a potential end to the downward cycle [2] Group 3 - The market is expected to maintain a trend of oscillating upward in September, although at a potentially slower rate compared to August, driven by positive feedback from incremental capital inflows [3] - The external environment appears stable, with high expectations for the Federal Reserve to initiate interest rate cuts, enhancing the attractiveness of RMB assets [3]

Financial Performance - The company achieved a revenue of CNY 1.163 billion in the first half of 2025, representing a year-on-year growth of 30.38% [2] - The net profit attributable to shareholders reached CNY 335 million, marking a significant increase of 97.75% compared to the same period last year [2] Dividend Distribution - The board approved a cash dividend plan of CNY 7 per 10 shares based on a total share capital of 245 million shares, pending approval at the upcoming shareholder meeting [3] Product Promotion and Market Strategy - The sales team for the promotion of atropine has over 500 members, focusing on disease education and product promotion through professional associations [4] - The product has been widely adopted in public hospitals and major private eye care groups, with distribution in nearly 17,000 retail pharmacies and online platforms [5] Research and Development - The company is advancing its innovative product pipeline, including the SQ-22031 eye drops, which are in Phase II clinical trials for neurotrophic keratitis [6] - The 0.01% atropine eye drops have been approved for market entry, with ongoing development of different concentrations (0.02% and 0.04%) for myopia control [5][17] Market Outlook - The near-sighted population among school-aged children in China exceeds 100 million, indicating a vast market potential for myopia prevention products [17] - The company plans to enhance its marketing strategies and expand its market share through comprehensive disease education and collaboration with various stakeholders [10][17] Sales Channels and Distribution - The company employs a multi-channel strategy, integrating both hospital and retail pharmacy sales to improve drug accessibility [9] - The sales contribution from public and private hospitals is crucial, while retail pharmacies and online platforms support patient repurchase [9][10] Future Development Plans - The company is focusing on establishing a new R&D center aimed at enhancing its capabilities in ophthalmic drug development [18] - Plans to expand into international markets are in preliminary discussions, with a focus on maintaining a stable pricing strategy for atropine despite emerging competition [15][13]